Context We present an overview of the updated 2023 European Association of Urology
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …

Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

Loss of the Y chromosome (LOY) is observed in multiple cancer types, including 10–40% of
bladder cancers,,,,–, but its clinical and biological significance is unknown. Here, using …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

Single-cell sequencing, including genomics, transcriptomics, epigenomics, proteomics and
metabolomics sequencing, is a powerful tool to decipher the cellular and molecular …